Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy Weiss L et al. J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):390-8 Posted on August 24th, 2016 - Pr François Raffi Back to Home page
Back to Home page